Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03829410
Title Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Trovagene, Inc.

colon cancer

rectum cancer


Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic Cancer Center Recruiting Phoenix Arizona 85054 United States Details
CARTI Cancer Center Recruiting Little Rock Arkansas 72205 United States Details
USC Norris Comprehensive Cancer Center Recruiting Los Angeles California 90033 United States Details
Mayo Clinic Florida Recruiting Jacksonville Florida 32224 United States Details
University of Kansas Medical Center Research Institute Recruiting Kansas City Kansas 66160 United States Details
Mayo Clinic Rochester Recruiting Rochester Minnesota 55905 United States Details
Inova Schar Cancer Institute Recruiting Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from for the field